Showing results (11-20 of 478) with videos related to
Sort By:
Pageof 48
Pharmacological Research|November 20, 2001
PPARS, metabolic disease and atherosclerosisJ C Fruchart, B Staels, P DuriezJournal De La Societe De Biologie|June 14, 2000
[Molecular mechanism of action of the fibrates]J C Fruchart, P Duriez, B StaelsBritish Journal of Clinical Practice. Supplement|June 6, 2009
Lipoprotein(a) as a marker for coronary heart diseaseP Duriez, J Dallongeville, J C FruchartCurrent Atherosclerosis Reports|December 21, 2000
The role of fibric acids in atherosclerosisJ C Fruchart, B Staels, P DuriezBulletin De L'Academie Nationale De Medecine|July 28, 2001
[New concepts on the mechanism of action of fibrates and therapeutic prospectives in atherosclerosis]J C Fruchart, B Staels, P DuriezBritish Journal of Clinical Practice. Supplement|January 1, 1996
Lipoprotein(a) as a marker for coronary heart diseaseP Duriez, J Dallongeville, J C FruchartJournal of Cardiovascular Risk|January 27, 1999
Alpha-tocopherol but not beta-tocopherol inhibits thrombin-induced PKC activation and endothelin secretion in endothelial cellsF Martin-Nizard, A Boullier, J C Fruchart, et al.Free Radical Biology & Medicine|July 13, 1999
Structure-activity relationships in a series of melatonin analogues with the low-density lipoprotein oxidation modelA Gozzo, D Lesieur, P Duriez, et al.Journal of Biochemical and Molecular Toxicology|September 16, 1999
Differential toxicities of air (mO-LDL) or copper-oxidized LDLs (Cu-LDL) toward endothelial cellsC Furman, F Martin-Nizard, J C Fruchart, et al.FEBS Letters|January 4, 1988
Preformed PAF-acether and lyso PAF-acether are bound to blood lipoproteinsJ Benveniste, D Nunez, P Duriez, et al.Pageof 48